OCC Orthocell Ltd
- 1.490
- +0.040+2.76%
Orthocell Ltd News
Those Who Invested in Orthocell (ASX:OCC) a Year Ago Are up 235%
Orthocell Files Premarket Application With US FDA for Nerve Repair Device; Shares Down 5%
Orthocell Submits FDA Application for Remplir With Eye on "Largest Healthcare Market in the World"
Year Wrapped: Orthocell Targets 2025 Growth With FDA Plans & Product Launches | ASX:OCC, OTC:ORHHF
Orthocell Passes Commercialisation Milestone With First Remplir Sales in Singapore
Orthocell Passes Commercialisation Milestone With First Remplir Sales in Singapore | ASX:OCC, OTC:ORHHF
Orthocell Secures First Orders for Nerve Repair Device in Singapore; Shares Up 5%
Orthocell Ltd Director Acquires New Performance Rights
Orthocell Ltd Issues New Equity Securities for Growth
Just the Facts: Orthocell Achieves FDA Study Milestone for Remplir Nerve Repair Product | ASX:OCC, OTC:ORHHF
Why This ASX Healthcare Share Is Soaring 26% on Study Findings
Orthocell Ever Closer to US Remplir Launch as It Wraps up Regulatory Study for FDA Clearance
Orthocell's Global Expansion Continues With Device Technologies Asia Deal | ASX:OCC, OTC:ORHHF
Small Cap Wrap: European Lithium a Strong Mover of the Week | ASX:OCC, OTC:ORHHF
Orthocell Ltd Initiates Trading Halt for Key Update
Orthocell Taps Singaporean Distributor for Nerve Repair Device; Shares Hit New 52-Week High
Orthocell Expands Remplir Sales Into Critical Asian Market With Distribution Agreement in Singapore
Orthocell Has Strategy Validated With A$17 Million Raised to Fund US Launch of Remplir and Drive Commercialisation
Orthocell Ltd Announces AGM and Global Expansion
Orthocell Ltd: Annual Report to Shareholders
No Data